NRX Pharmaceuticals (NRXP) Common Equity (2017 - 2026)

NRX Pharmaceuticals (NRXP) has reported Common Equity for 10 consecutive years, with -$200000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity rose 99.44% year-over-year to -$200000.0 in Q2 2026; TTM through Jun 2026 was -$200000.0, a 99.44% increase from a year earlier, with the FY2025 full-year figure at -$15.9 million, up 31.37% from the prior year.
• Common Equity was -$200000.0 for Q2 2026 at NRX Pharmaceuticals, up from -$13.8 million in the prior quarter.
• Over five years, Common Equity peaked at $31.7 million in Q1 2022 and troughed at -$35.6 million in Q2 2025.
• A 5-year average of -$7.3 million and a median of -$12.8 million in 2023 frame the typical range for Common Equity.
• Across the five-year window, Common Equity soared 395.84% in 2022 and slumped 5205.99% in 2024, its largest moves.
• Over 5 years, Common Equity stood at $7.4 million in 2022, then slumped by 258.36% to -$11.7 million in 2023, then slumped by 97.93% to -$23.2 million in 2024, then soared by 31.37% to -$15.9 million in 2025, then surged by 98.75% to -$200000.0 in 2026.
• The last three Common Equity figures came in at -$200000.0 (Q2 2026), -$13.8 million (Q1 2026), and -$15.9 million (Q4 2025), per Business Quant data.